Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Altimmune (ALT) over the last 14 years, with Q3 2025 value amounting to $8.7 million.

  • Altimmune's Gains from Investment Securities rose 3537.25% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 3537.25%. This contributed to the annual value of $6.6 million for FY2024, which is 3146.34% up from last year.
  • Latest data reveals that Altimmune reported Gains from Investment Securities of $8.7 million as of Q3 2025, which was up 3537.25% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Gains from Investment Securities ranged from a high of $8.7 million in Q3 2025 and a low of -$1.8 million during Q1 2022
  • In the last 5 years, Altimmune's Gains from Investment Securities had a median value of $3.4 million in 2022 and averaged $3.4 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 17848.72% in 2022, then surged by 130483.3% in 2025.
  • Over the past 5 years, Altimmune's Gains from Investment Securities (Quarter) stood at -$860000.0 in 2021, then skyrocketed by 114.53% to $125000.0 in 2022, then crashed by 70.4% to $37000.0 in 2023, then crashed by 94.59% to $2000.0 in 2024, then skyrocketed by 432967.85% to $8.7 million in 2025.
  • Its Gains from Investment Securities stands at $8.7 million for Q3 2025, versus $8.1 million for Q2 2025 and $8.4 million for Q1 2025.